Description :

According to a new market report published by U.S. based market research company, Transparency Market Research “Osteoporosis Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends & Forecast, 2014 - 2020” the global osteoporosis drugs market was valued at USD 8.4 billion in 2013 and is estimated to reach a market worth of USD 8.9 billion in 2020 growing at a CAGR of 1.2% from 2014 to 2020.

Steadily rising prevalence of osteoporosis is an important healthcare issue on a worldwide level. Osteoporosis is a bone disorder, in which, the bone mass and bone density are depleted leading to alteration in bone microstructure. This condition enhances the threat of bone crack and bone fractures. Hence, elevation in threat of bone cracks and introduction of new drug therapy classes are the factors that are fuelling the growth of osteoporosis drugs market. Since there is no distinct substitute available to treat osteoporosis (such as, surgery), the drugs therapy is an inevitable part of osteoporosis treatment

Browse the full Osteoporosis Drugs Market Report at :
http://www.transparencymarketresearch.com/osteoporosis-drug-market.html

Osteoporosis drugs market is segmented on the basis of drug classes used to treat the disease. Amongst all the drug classes the global osteoporosis drugs market is dominated by bisphosphonates segment accounting for a market share of 48.2% in 2013. However, during the forecast period the class is expected to report a negative CAGR due to expiry of drugs (Reclast and Boniva) and frequent evidences of chronic side-effects. In addition, owing to year on year decline in the sales of Fosamax, highest revenue generating drug of this class is also expected to pull back the growth of this market. On the contrary, the class is expected to retain its dominant position in the market in terms of revenue due to first mover advantage and extensive prescriptions of bisphosphonates in osteoporosis treatment. Similarly, SERM drug class which occupied second largest share of the market in 2013 is expected to heavily decline its market share due to patent expiry of its blockbuster drug Evista in 2014. However, demand for calcium and vitamin D will remain high during the forecast period. This is because; calcium and vitamin D supplements are used as first line as well as prolonged term treatment with osteoporosis. Although available as over-the-counter (OTC) drugs, the sales revenue generated by these drugs is considerably high and is estimated to increase during the forecast period.

Get Free Sample Report Osteoporosis Drugs Market :
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=133

Currently, certain novel compounds for the treatment of osteoporosis are under investigation in both preclinical and clinical settings. Some of the major candidates such as Odanacatib, Romosozumab and others are currently in phase III clinical trials. These drugs promise fewer side effects as compared to the currently available drugs and provide improved efficacy. Hence, expected launch of these drugs during the forecast period is anticipated to have significant impact on the growth of the overall osteoporosis drugs market.

Browse the full Osteoporosis Drugs Market press release at :
http://www.transparencymarketresearch.com/pressrelease/osteoporosis-drugs-market.htm

In 2013, the North American region was the largest market in the world, owing to high prevalence of osteoporosis and rising demand for newly introduced drugs as well as generic formulations of the established drugs. Additionally, change in dietary habits and decrease in calcium and vitamin D intake also accentuated the growth of the market in this region. However, Asia-Pacific region is estimated to witness strong growth in its market share and emerge as the most promising and fastest growing market in the forecast period 2014 to 2020. The growth is expected to be driven by factors such as steadily increasing osteoporosis population, increased awareness towards diagnosis and management of osteoporosis and preference of population towards drugs with less side-effect. Moreover, steadily increasing technological utilization, such as, DXA instrument, is also anticipated to favor the growth of osteoporosis drugs market in this region.

The market is consolidated and is dominated by selective players operating on a global level, such as, Eli Lilly and Company, Pfizer, Inc., Amgen, Inc., Merck, Inc., and Novartis International AG. In 2013, Eli Lilly and Company was the market leader in osteoporosis drugs market, followed by Pfizer, Inc. and Amgen, Inc. Companies in this market are adopting strategies of partnership and collaboration to increase their market presence.


The global osteoporosis drugs market is segmented as follows:

Global Osteoporosis Drugs Market, by Drugs Class

Bisphosphonates

Calcitonin

RANK Ligand Inhibitors

Parathyroid Hormone Therapy (PTH)

Selective Estrogen Receptor Modulators (SERMs)

Global Osteoporosis Drugs Market, by Geography

North America

Europe

Asia-Pacific

Rest of the World (RoW)

About Us :

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.